# Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

> **NCT04959032** · PHASE3 · COMPLETED · sponsor: **Intra-Cellular Therapies, Inc.** · enrollment: 228 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lumateperone 42 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04959032
- **Lead sponsor:** Intra-Cellular Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-08
- **Primary completion:** 2024-07-25
- **Final completion:** 2024-08-07
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04959032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04959032, "Lumateperone for the Prevention of Relapse in Patients With Schizophrenia". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04959032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*